Enhancing CLIA Act Proposes Updated LDT Oversight Under CMS

The Enhancing CLIA Act proposes to modernize regulatory oversight of laboratory-developed tests (LDTs) by reaffirming CMS authority under the CLIA framework rather than FDA device regulation, aiming to reflect advances in molecular diagnostics and genomic medicine with new transparency and reporting requirements.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure.